SS Innovations International (NASDAQ: SSII) has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic left internal mammary artery (LIMA) take-down performed using the SSi Mantra 3.0 system. The procedure was led by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, with support from the SS Innovations team. This development matters because it demonstrates the growing adoption of robotic-assisted cardiac surgery in India, a country with a high burden of cardiovascular disease, and positions SS Innovations as a key player in the global surgical robotics market.
The company reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka, and the Philippines. This rapid installation growth and geographic diversification highlight the increasing demand for affordable, advanced robotic surgical solutions, particularly in emerging markets where access to such technology has historically been limited. The expansion into new countries also suggests that SS Innovations is successfully navigating regulatory and market-entry challenges, which could pave the way for further international growth.
SS Innovations is pursuing U.S. FDA review and European Union CE marking as it seeks to expand SSi Mantra into additional international markets. Achieving these regulatory milestones would be significant, as it would allow the company to compete in the largest and most lucrative healthcare markets. The FDA review and CE marking are critical steps for any medical device company seeking global acceptance, and success in these endeavors could substantially increase SS Innovations' addressable market and revenue potential.
The launch of the robotic cardiac surgery program at HCG Hospital is a testament to the trust that leading healthcare institutions are placing in SS Innovations' technology. In a LinkedIn post, the company congratulated Dr. Brajmohan Singh, Dr. Lalit Malik, and the entire team at HCG Hospital for this achievement, thanking them for their trust and commitment to advancing robotic cardiac surgery in the region. For more details, see the full announcement on www.newmediawire.com.
The implications of this announcement extend beyond a single hospital program. Robotic cardiac surgery offers potential benefits such as smaller incisions, reduced pain, and faster recovery times compared to traditional open-heart surgery. By enabling hospitals like HCG to offer these advanced procedures, SS Innovations is helping to raise the standard of care in India and other markets. Moreover, the company's focus on cost-effective solutions could make robotic surgery more accessible in resource-constrained settings, addressing a significant unmet need.
Investors and industry observers will be watching SS Innovations closely as it pursues regulatory approvals and expands its global presence. The company's ability to execute on its growth strategy, including securing FDA clearance and CE marking, will be crucial to its long-term success. For now, the launch of the cardiac program at HCG Hospital represents a tangible step forward in the company's mission to transform surgical care through robotics. Additional information about SS Innovations International is available at SS Innovations International (NASDAQ: SSII), and the latest news and updates relating to SSII can be found at https://ibn.fm/SSII. As with any forward-looking statements, there are risks and uncertainties that could cause actual results to differ materially, and readers are encouraged to review the full disclaimers at https://IBN.ai/Disclaimer.
